Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: Increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin

Diabetes, Obesity and Metabolism

Volumn 16, Issue 10, 2014, Pages 881-884

  Currie, Craig J ^a   Holden, S E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; INCRETIN; SULFONYLUREA DERIVATIVE;

ADVERSE OUTCOME; CANCER RISK; CEREBROVASCULAR ACCIDENT; EDITORIAL; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; MONOTHERAPY; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; RISK REDUCTION; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 84912102131     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12349     Document Type: Editorial

References (54)

1. Holden SE, Currie CJ. Mortality risk with sulphonylureas compared to metformin. Diabetes Obes Metab 2014; 16: 885-890.
2. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497-502.
3. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J 2006; 174: 169-174.
4. Schernthaner G, Currie CJ, Schernthaner G-H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013; 36(Suppl. 2): S155-S161.
5. Zou C, Hu H. Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vasc Health Risk Manag 2013; 9: 429-433.
6. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus comparison with other oral antihyperglycaemic agents. Drugs 2010; 70: 1945-1961.
7. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 4605-4612.
8. Mogensen UM, Andersson C, Fosbøl EL et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study. Diabetes Obes Metab 2014; 16: 1001-1008.
9. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014; 16: 977-983.
10. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-3323.
11. Cobble M. Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2012; 4: 8.
12. 1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
13. Klein K, Best JH, Marso SP, Maggs D, Paul SK. Long-term cardiovascular outcomes with exenatide twice daily compared to insulin: a retrospective observational study. Diabetologia 2013; 56(Suppl. 1): S393.
14. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013; 98: 668-677.
15. Gamble J-M, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010; 12: 47-53.
16. Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L, Euro Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008; 29: 177-184.
17. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17: 753-759.
18. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with amarked increase inmortality in patients with advanced heart failure. AmHeart J 2005; 149: 168-174.
19. Hall GC, McMahon AD, Carroll D, Home PD. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. Pharmacoepidemiol Drug Saf 2012; 21: 305-313.
20. Holden SE, Schernthaner G, Jenkins-Jones S, Currie CJ. Exogenous insulin and risk of all-cause mortality in type 2 diabetes: a dose-response association. Diabetologia 2013; (Suppl. 1): S96.
21. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab 2012; 14: 424-432.
22. Leese GP, Wang J, Broomhall J et al. DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 1176-1180.
23. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552-1561.
24. Liu HY, Cao SY, Hong T, Han J, Liu Z, Cao W. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem 2009; 284: 27090-27100.
25. Després JP, Lamarche B, Mauriège P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
26. Antoniades C, Tousoulis D, Marinou K et al. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetesmellitus and coronary atherosclerosis. Clin Cardiol 2007; 30: 295-300.
27. Westerbacka J, Tamminen M, Cockcroft J, Yki-Järvinen H. Comparison of in vivo effects of nitroglycerin and insulin on the aortic pressure waveform. Eur J Clin Invest 2004; 34: 1-8.
28. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 1999; 33: 1118-1122.
29. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
30. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
31. FDA Briefing Document. NDA 203313 and NDA 203314. Insulin Degludec and Insulin Degludec/Aspart. Available from URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologic andmetabolicdrugsadvisorycommittee/ucm327015.pdf. Accessed 27 May 2014.
32. Roumie CL, Greevy RA, Grijalva CG et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014; 311: 2288-2296.
33. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 938-953.
34. Hemmingsen B, Schroll JB, Lund SS et al. Sulfonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 4: CD009008.
35. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891.
36. Wang L, Cai S, Teng Z, Chen X, Bai X. Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis. Diagn Pathol 2013; 8: 180.
37. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab 2012; 38: 485-506.
38. Janghorbani M, Dehghani M, Salehi-Marzijarani M. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 2013; 3: 137-146.
39. Franciosi M, Lucisano G, Lapice E, Strippoli GFM, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes. PLoS One 2013; 8: e71583.
40. The ORIGIN Investigators T. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
41. Yeap BB, Alfonso H, Chubb SA et al. Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab 2012; 97: 4030-4039.
42. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124: 1398-1403.
43. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Circulation 1996; 94: 2297-2301.
44. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
45. Holman RR, Paul SK, Bethel MA, Matthews DR. Neil HA.10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
46. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
47. ADVANCE Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
48. Duckworth W, Abraira C, Moritz T et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
49. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014; 174: 1227-1234.
50. Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes. Diabetes Care 2011; 34: 77-83.
51. Nolan CJ, Ruderman NB, Prentki M. Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes Endocrinol 2013; 1: 9-10.
52. Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012; 14: 1-4.
53. Holden SE, Schernthaner G, Jenkins-Jones S, Currie CJ. Exogenous insulin and risk of all-cause mortality in type 2 diabetes: a dose-response association. Available from URL: http://www.easdvirtualmeeting.org/resources/7049. Accessed 27 May 2014.
54. Home P, Riddle M, Cefalu WT et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 2014; 37: 1499-1508.